BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Europe

Alkermes Advances Orexin-Based Depression Treatment into Phase II Clinical Trial

Alkermes plc announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants ...

November 01, 2026 | News

Pretzel Therapeutics Secures UK Approval to Advance PX578 into Phase II Trial for Rare Mitochondrial Disease

Regulatory milestone follows U.S. FDA clearance of Investigational New Drug application in August 2026 Initiation of Phase 2 Trial in POLG-PMD (POLG Dis...

November 01, 2026 | News

Immunome’s Varegacestat Moves into European Regulatory Review Following Positive Phase III Results

The Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically significant improvements ac...

November 01, 2026 | News

Parse Biosciences and Nomic Bio Launch 100-Million-Cell Immune Dataset to Advance AI Drug Discovery

Parse Biosciences, a leading provider of scalable and publicly available single-cell sequencing technology, a subsidiary of QIAGEN, andNomic Bio, a leader ...

November 01, 2026 | News

17 APAC-Made Biosimilars Approved in the US or EU in 2026

Seventeen times in 2026, the US Food and Drug Administration or the European Commission cleared a biosimilar that was developed or made in Asia-Pacific. Ni...

October 28, 2026 | Analysis

EU Approves Daiichi Sankyo and AstraZeneca’s Enhertu for Early HER2-Positive Breast Cancer

Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive diseas...

October 28, 2026 | News

Menarini and Georgiamune Strike $1.1 Billion Licensing Deal to Advance Next-Generation Cancer Immunotherapy

GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. Georgiamune to...

October 27, 2026 | News

Harbour BioMed Secures China’s NMPA Approval for Batoclimab, Expanding Treatment Options for Myasthenia Gravis

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...

October 26, 2026 | News

Samsung Biologics Reports KRW 1.49 Trillion Q3 Revenue as Global Manufacturing Expansion Drives Growth

Recorded Q3'26 revenue of KRW 1,490 billion and operating profit of KRW 640 billion Plant 5 ramp-up and U.S. manufacturing operations contribute to earn...

October 23, 2026 | Company results

Therakos Secures EU MDR Approval for First-of-Its-Kind Therapy to Manage Cancer Immunotherapy Toxicities

Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal photopheresis (ECP), announced t...

October 23, 2026 | News

Merck to Acquire Silence Therapeutics for $1.3 Billion, Expanding Rare Disease Portfolio with siRNA Innovation

Purchase price of $20 per ADS in cash represents an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion Silence Therapeut...

October 22, 2026 | News

AstraZeneca and Oracle Join Forces to Harness AI and Real-World Data for Smarter Clinical Trials

Collaboration to connect AstraZeneca's scientific and therapeutic expertise with Oracle's real-world data, cloud, AI, and clinical capabilities to accelera...

October 21, 2026 | News

Nuevocor Doses First Patient in Phase 1/2 Gene Therapy Trial for Inherited Cardiomyopathy

Nuevocor, a clinical-stage biotechnology company pioneering mechanobiology-targeted therapies designed to address the root causes of life-threatening...

October 13, 2026 | News

12 APAC-Originated Programmes to Watch at ESMO 2026

When the ESMO Congress 2026 opens at IFEMA Madrid on Friday 23 October, the region that most European oncologists still think of as a fast follower will ho...

October 13, 2026 | News

Stay Connected